semaglutide - Profile

What are the generic sources for semaglutide and what is the scope of freedom to operate?

Semaglutide is the generic ingredient in three branded drugs marketed by Novo and is included in four NDAs. There are thirty-seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Semaglutide has four hundred and fifty patent family members in thirty-eight countries.

Summary for semaglutide

International Patents:	450
US Patents:	37
Tradenames:	3
Applicants:	1
NDAs:	4
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for semaglutide

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for semaglutide

Constraining patent/regulatory exclusivity:

8,129,343

Dosage:

SOLUTION;SUBCUTANEOUS

Constraining patent/regulatory exclusivity:

10,933,120

Dosage:

TABLET;ORAL

Constraining patent/regulatory exclusivity:

8,129,343

Dosage:

SOLUTION;SUBCUTANEOUS

Constraining patent/regulatory exclusivity:

9,278,123

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for SEMAGLUTIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYBELSUS	Tablets	semaglutide	1.5 mg, 4 mg and 9 mg	213051	1	2025-12-11
RYBELSUS	Tablets	semaglutide	3 mg, 7 mg and 14 mg	213051	1	2024-07-15
OZEMPIC	Injection	semaglutide	2 mg/3 mL	209637	1	2024-04-11
OZEMPIC	Injection	semaglutide	8 mg/3 mL	209637	1	2022-12-21
WEGOVY	Injection	semaglutide	0.25 mg/0.5 mL 0.5 mg/0.5 mL 1 mg/0.5 mL 1.7 mg/0.75 mL 2.4 mg/0.75 mL	215256	1	2022-10-20
OZEMPIC	Injection	semaglutide	2 mg/1.5 mL and 4 mg/3 mL	209637	7	2021-12-06

US Patents and Regulatory Information for semaglutide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-001	Dec 5, 2017		DISCN	Yes	No	8,129,343		Y	Y
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-001	Dec 5, 2017		DISCN	Yes	No	8,536,122		Y	Y
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-001	Dec 5, 2017		DISCN	Yes	No	10,335,462
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-001	Dec 5, 2017		DISCN	Yes	No	9,687,611		Y		Y
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-001	Dec 5, 2017		DISCN	Yes	No	10,376,652		Y		Y

Expired US Patents for semaglutide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-002	Apr 9, 2019	6,899,699
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-004	Oct 6, 2022	8,114,833
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-002	Apr 9, 2019	9,108,002
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-004	Oct 6, 2022	10,357,616
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-002	Apr 9, 2019	10,357,616

EU/EMA Drug Approvals for semaglutide

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novo Nordisk A/S	Wegovy	semaglutide	EMEA/H/C/005422Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to	Authorised	no	no	no	2022-01-06
Novo Nordisk A/S	Ozempic	semaglutide	EMEA/H/C/004174Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2018-02-08
Novo Nordisk A/S	Rybelsus	semaglutide	EMEA/H/C/004953Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin combination with other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2020-04-03

International Patents for semaglutide

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2010046394
Hungary	E039406
Spain	2796839
China	115461072
European Patent Office	4106724

Supplementary Protection Certificates for semaglutide

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1863839	2018/017	Ireland		PRODUCT NAME: OZEMPIC-SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180208
1863839	300936	Netherlands		PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180208
1863839	SPC/GB18/023	United Kingdom		PRODUCT NAME: SEMAGLUTIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/17/1251 (NI) 20180208; UK PLGB 04668/0331 20180208; UK PLGB 04668/0332 20180208; UK PLGB 04668/0333 20180208
1863839	1890018-3	Sweden		PRODUCT NAME: SEMAGLUTIDE; REG. NO/DATE: EU/1/17/1251 20180212
1863839	122018000075	Germany		PRODUCT NAME: OZEMPIC-SEMAGLUTID; REGISTRATION NO/DATE: EU/1/17/1251 20180208

Semaglutide: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk, has established itself as a leading therapeutic agent in the treatment of type 2 diabetes mellitus (T2DM) and obesity. Its exceptional efficacy in glycemic control and weight loss has fueled robust market growth and attracted significant investor focus. This report examines semaglutide’s current market landscape, growth drivers, competitive environment, and financial outlook, with a focus on near-term and long-term investment prospects.

---

What Is Semaglutide and Its Therapeutic Profile?

Aspect	Details
Brand Names	Ozempic (T2DM), Wegovy (Obesity)
Developer	Novo Nordisk
FDA Approval Dates	Ozempic: 2017; Wegovy: 2021
Indications	T2DM management, weight management
Administration	Subcutaneous injection
Dosage Forms	Weekly injection
Mechanism of Action	GLP-1 receptor agonist enhances insulin secretion, suppresses glucagon, reduces appetite

---

Market Dynamics

Global Market Size and Growth Projections

Year	T2DM Market (USD billion)	Obesity Market (USD billion)	Compound Annual Growth Rate (CAGR)	Source
2022	20.1	13.0	8.4% (T2DM), 12.1% (Obesity)	[1], [2]
2027	33.2	27.4	8.4%, 12.1%	[1], [2]

Sources: [1] IQVIA, 2023; [2] Global Market Insights, 2023

Key Drivers

• Efficacy & Safety: Semaglutide’s superior glycemic and weight loss outcomes over competitors.
• Line Extension & Approvals: New formulations (e.g., oral semaglutide) expanding accessible patient populations.
• Regulatory Approvals: US FDA, EMA approvals for weight management, expanding indications.
• Increasing T2DM & Obesity Prevalence: Global rise in metabolic disorders, especially in emerging markets.
• Patient Preference: Weekly dosing enhances adherence compared to daily medications.

Competitive Landscape

Competitors	Key Products	Market Share (Estimated)	Differentiators
Eli Lilly	Tirzepatide (Mounjaro)	~20%	Dual GIP/GLP-1 receptor agonist, superior weight loss
AstraZeneca	Bydureon, Trulicity	~15%	Established GLP-1 therapies
Novo Nordisk	Ozempic, Wegovy, Rybelsus	~50%	Focused portfolio, multiple indications

Market position: Semaglutide holds approximately 50% market share in the GLP-1 space, driven by efficacy and market expansion.

---

Financial Trajectory Analysis

Revenue Growth and Key Financial Metrics

Year	Estimated Revenue (USD billion)	Growth %	Main Drivers
2022	$6.0	—	Launch of Wegovy, increased prescriptions in T2DM
2023	$9.2	+53%	Expanded indications, oral formulation launch
2024	$13.5	+47%	Broader acceptance, emerging markets penetration
2025	$19.4	+44%	Growth in obesity market, potential new formulations
2030	$35.0+	—	Strategic pipeline expansion, potential biosimilars

Profitability Outlook

• Gross Margins: Typically ~70%
• Operating Margins: Projected ~40-45%
• R&D Investment: ~20% of revenue annually, focusing on next-generation GLP-1 and combination therapies.

Valuation and Investment Consideration

• Current Market Cap: Approximately $250 billion (as of early 2023).
• Price-to-Earnings (P/E): Estimated >30x, reflecting high growth expectations.
• Pipeline Impact: Positive anticipation for oral formulations, fixed-dose combinations, and new indications.

---

Comparison with Competitors

Aspect	Semaglutide (Novo Nordisk)	Tirzepatide (Eli Lilly)	Bydureon (AstraZeneca)
Efficacy (HbA1c reduction)	~1.5-2.0%	~2.0-2.5%	~1.0-1.5%
Weight Loss (kg)	10-15kg	12-20kg	5-9kg
Dosing	Weekly	Weekly	Weekly
Market Penetration	Highest among GLP-1s	Rapidly Growing	Mature but Competitive

Note: Tirzepatide shows promise for superior efficacy but is still undergoing regulatory review; its launch may shift market dynamics.

---

Market Growth Opportunities & Risks

Opportunities

• Expanding Indications: Cardiovascular, NAFLD/NASH, and other metabolic disorders.
• Innovative Formulations: Oral semaglutide offers broader patient acceptance.
• Emerging Markets: Increased prevalence and healthcare investments.

Risks

• Patent Expirations: Patent cliffs threatening exclusivity post-2030.
• Pricing Pressures: Payer negotiations and drug reimbursement policies.
• Regulatory Risks: Delays or adverse data impacting approval pathways.
• Competition: Entry of biosimilars and novel agents.

---

Deep Dive: Regulatory and Policy Landscape

Region	Key Policies	Impact on Semaglutide	Comments
US FDA	Accelerated approval pathways, price negotiations	Favorable if demonstrating superiority	Payer discounting could pressure margins
EU EMA	Centralized approval, cost-containment policies	Similar approval pathway	Reimbursement negotiations essential
China	Rapid approval for innovative medicines	Growing market, registration speed critical	Increasing health expenditure, rising prevalence
Emerging Markets	Price controls, local manufacturing	Price sensitivity may limit access	Opportunities for licensing or partnerships

---

Conclusion: Investment Outlook for Semaglutide

Semaglutide's strong clinical efficacy, expanding indications, and growing global markets position it as a high-growth asset in the pharmaceutical landscape. Novo Nordisk's strategic pipeline and market penetration reinforce its leadership. However, patent expiration risks and intense competition necessitate vigilant monitoring. The compound's valuation reflects high growth expectations, supported by substantial revenue and profit trajectory.

---

Key Takeaways

• Semaglutide is a cornerstone product with diversified applications in diabetes and obesity, promising sustained revenue growth.
• Market expansion hinges on regulatory approvals, oral formulations, and emerging market penetration.
• Competitive landscape includes Eli Lilly’s tirzepatide, which may challenge semaglutide’s dominance in the near future.
• Investment opportunities are buoyed by innovative formulations, increased indications, and global health trends but are tempered by patent risks and intensifying pricing pressures.
• Long-term growth depends on pipeline success, regulatory environment, and strategic responses to biosimilar threats.

---

FAQs

1. What are the main drivers behind semaglutide’s market growth?
Clinical efficacy, weekly dosing convenience, expanded indications (T2DM and obesity), regulatory approvals for new formulations (like oral semaglutide), and increasing global prevalence of metabolic disorders.

2. How does semaglutide compare to its competitors?
Semaglutide offers superior efficacy in glycemic control and weight loss compared to predecessors like dulaglutide or liraglutide, with Eli Lilly’s tirzepatide emerging as a potent competitor due to dual GIP/GLP-1 activity.

3. When are patent expirations expected, and how might they impact the market?
Patent protection for primary products extends to approximately 2030. Afterward, biosimilars could introduce price competition, potentially reducing margins.

4. What new indications or formulations are in development?
Research includes cardiovascular benefits, NASH, and oral formulations, which aim to broaden market access and adherence.

5. What are the main risks to semaglutide’s long-term investment prospects?
Patent cliff, pricing pressures, regulatory delays, and competitive advances from biosimilars or novel therapeutics.

---

References

[1] IQVIA, "Global Medicine Market Report," 2023.
[2] Global Market Insights, “Metabolic Disorder Therapeutics,” 2023.